Deutsche Märkte öffnen in 38 Minuten

Medigene AG (MDG1.DE)

XETRA - XETRA Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
1,5900-0,1300 (-7,56%)
Börsenschluss: 05:36PM CEST

Medigene AG

Lochhamer Strasse 11
Planegg/Martinsried
Munich 82152
Germany
49 89 2000 330
https://www.medigene.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 76

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Selwyn Ho MB BS, MBBSCEO & Member of Executive Management Board384,47kN/A1971
Dr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & Development600kN/AN/A
Dr. Ernst-Ludwig WinnackerCo-Founder & Chairman Scientific Advisory Board20kN/A1941
Dr. Birger KohlertChief Financial OfficerN/AN/AN/A
Pamela KeckVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Dr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Corporate Governance

Medigene AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.